Prothrombin Complex Concentrate
Phase 3Small molecule
CSL BehringProthrombin Complex Concentrate is one of 44 small molecule programs targeting Bleeding. It is currently in Phase 3.
2
Indications
14
Total Trials
3
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
96 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Darbepoetin
BayerPhase 3
Rezzayo
MMundipharma (China) Pharmaceutical Co. Ltd
Phase 3
Prothrombin Complex Concentrate
CSL BehringPhase 3
Tacrolimus Pill
EEdward Geissler
Phase 3
Lenvima
EisaiPreclinical
Octreotide
Johnson & JohnsonPreclinical
Beyfortus
BeiGenePreclinical
Prostigmin
Merck & Co.Preclinical
Myfortic
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiac Surgery3 trials
Surgery2 trials
Intracranial Hemorrhage1 trial
Coagulopathy1 trial
REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy
Unknown status·—·Phase 2·NCT03981484·280 enrolled
6 more indications
Efficacy and Safety1 trial
Neurosurgical Patients1 trial
Bleeding1 trial
Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06627218·650 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company